What question did this study set out to answer?

To determine how flow cytometry can guide drug sensitivity testing for venetoclax in acute undifferentiated leukaemia.

April 19, 2026

Flow cytometry‐guided ex vivo drug sensitivity testing informs venetoclax‐based therapy in acute undifferentiated leukaemia

LXLei XuChinese PLA General Hospital YWYì WángBGI Group (China)WZWen ZhaoHuazhong Agricultural University

Key Points

To determine how flow cytometry can guide drug sensitivity testing for venetoclax in acute undifferentiated leukaemia.
Utilized flow cytometry to assess drug sensitivity of leukemic cells
Conducted ex vivo testing to evaluate responses to venetoclax
Analyzed the data to inform therapeutic decisions
Flow cytometry effectively identified sensitive versus resistant leukemic cells to venetoclax
The findings indicate potential for improved therapy outcomes through personalized treatment approaches

Abstract

The data that support the findings of this study are available from the corresponding author upon reasonable request. Data S1. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.

اسأل الذكاء الاصطناعي

Bookmark

View Full Paper